Epizyme’s Tazemetostat Gains US FDA Panel Nod For Accelerated Approval In Epithelioid Sarcoma

 
• By Sue Sutter
  
FDA Advisory Committee Feature image
Oncologic Drugs Advisory Committee voted unanimously that tazemetostat's benefits outweigh its risks.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers